I-Mab Biopharma (IMAB) Misses Q2 EPS by 3c

I-Mab Biopharma (NASDAQ: IMAB) reported Q2 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• VNET Group (VNET) Misses Q2 EPS by 164c
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance